Your browser doesn't support javascript.
loading
Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial.
Greinacher, Andreas; Friesecke, Sigrun; Abel, Peter; Dressel, Alexander; Stracke, Sylvia; Fiene, Michael; Ernst, Friedlinde; Selleng, Kathleen; Weissenborn, Karin; Schmidt, Bernhard M W; Schiffer, Mario; Felix, Stephan B; Lerch, Markus M; Kielstein, Jan T; Mayerle, Julia.
Afiliação
  • Greinacher A; Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt-Universität, Greifswald, Germany. greinach@uni-greifswald.de
Lancet ; 378(9797): 1166-73, 2011 Sep 24.
Article em En | MEDLINE | ID: mdl-21890192
ABSTRACT

BACKGROUND:

In May 2011, an outbreak of Shiga toxin-producing enterohaemorrhagic E coli O104H4 in northern Germany led to a high proportion of patients developing post-enteritis haemolytic uraemic syndrome and thrombotic microangiopathy that were unresponsive to therapeutic plasma exchange or complement-blocking antibody (eculizumab). Some patients needed ventilatory support due to severe neurological complications, which arose 1 week after onset of enteritis, suggesting an antibody-mediated mechanism. Therefore, we aimed to assess immunoadsorption as rescue therapy.

METHODS:

In our prospective non-controlled trial, we enrolled patients with severe neurological symptoms and confirmed recent E coli O104H4 infection without other acute bacterial infection or raised procalcitonin concentrations. We did IgG immunoadsorption processing of 12 L plasma volumes on 2 consecutive days, followed by IgG replacement (0·5 g/kg intravenous IgG). We calculated a composite neurological symptom score (lowest score was best) every day and assessed changes before and after immunoadsorption.

FINDINGS:

We enrolled 12 patients who initially presented with enteritis and subsequent renal failure; 10 (83%) of 12 patients needed renal replacement therapy by a median of 8·0 days (range 5-12). Neurological complications (delirium, stimulus sensitive myoclonus, aphasia, and epileptic seizures in 50% of patients) occurred at a median of 8·0 days (range 5-15) and mandated mechanical ventilation in nine patients. Composite neurological symptom scores increased in the 3 days before immunoadsorption to 3·0 (SD 1·1, p=0·038), and improved to 1·0 (1·2, p=0·0006) 3 days after immunoadsorption. In non-intubated patients, improvement was apparent during immunoadsorption (eg, disappearance of aphasia). Five patients who were intubated were weaned within 48 h, two within 4 days, and two patients needed continued ventilation for respiratory problems. All 12 patients survived and ten had complete neurological and renal function recovery.

INTERPRETATION:

Antibodies are probably involved in the pathogenesis of severe neurological symptoms in patients with E coli O104H4-induced haemolytic uraemic syndrome. Immunoadsorption can safely be used to rapidly ameliorate these severe neurological complications.

FUNDING:

Greifswald University and Hannover Medical School.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Técnicas de Imunoadsorção / Infecções por Escherichia coli / Escherichia coli Shiga Toxigênica / Escherichia coli Êntero-Hemorrágica / Síndrome Hemolítico-Urêmica / Doenças do Sistema Nervoso Tipo de estudo: Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2011 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Técnicas de Imunoadsorção / Infecções por Escherichia coli / Escherichia coli Shiga Toxigênica / Escherichia coli Êntero-Hemorrágica / Síndrome Hemolítico-Urêmica / Doenças do Sistema Nervoso Tipo de estudo: Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2011 Tipo de documento: Article País de afiliação: Alemanha